Long-term platinum retention after treatment with cisplatin and oxaliplatin.

Elke E M Brouwers, Alwin D R Huitema, Jos H Beijnen, Jan H M Schellens
{"title":"Long-term platinum retention after treatment with cisplatin and oxaliplatin.","authors":"Elke E M Brouwers,&nbsp;Alwin D R Huitema,&nbsp;Jos H Beijnen,&nbsp;Jan H M Schellens","doi":"10.1186/1472-6904-8-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to evaluate long-term platinum retention in patients treated with cisplatin and oxaliplatin.</p><p><strong>Methods: </strong>45 patients, treated 8-75 months before participating in this study, were included. Platinum levels in plasma and plasma ultrafiltrate (pUF) were determined. In addition, the reactivity of platinum species in pUF was evaluated. Relationships between platinum retention and possible determinants were evaluated.</p><p><strong>Results: </strong>Platinum plasma concentrations ranged between 142-2.99 x 10(3) ng/L. Up to 24% of plasma platinum was recovered in pUF. No platinum-DNA adducts in peripheral blood mononuclear cells (PBMCs) could be detected. Ex vivo incubation of DNA with pUF of patients revealed that up to 10% of the reactivity of platinum species was retained. Protein binding proceeded during sample storage. Sodium thiosulfate (STS) appeared to release platinum from the plasma proteins. Platinum levels were related to time, dose, STS co-administration, and glomerular filtration rates (GFR).</p><p><strong>Conclusion: </strong>Our data suggest that plasma platinum levels are related to time, age, dose, GFR, and STS use. Platinum in plasma, probably, represent platinum eliminated from regenerating tissue. Platinum species in pUF were partly present in a reactive form. The effects of the reactivity on long-term consequences of Pt-containing chemotherapy, however, remains to be established.</p>","PeriodicalId":9196,"journal":{"name":"BMC Clinical Pharmacology","volume":"8 ","pages":"7"},"PeriodicalIF":0.0000,"publicationDate":"2008-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1472-6904-8-7","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1472-6904-8-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 18

Abstract

Background: The aim of this study was to evaluate long-term platinum retention in patients treated with cisplatin and oxaliplatin.

Methods: 45 patients, treated 8-75 months before participating in this study, were included. Platinum levels in plasma and plasma ultrafiltrate (pUF) were determined. In addition, the reactivity of platinum species in pUF was evaluated. Relationships between platinum retention and possible determinants were evaluated.

Results: Platinum plasma concentrations ranged between 142-2.99 x 10(3) ng/L. Up to 24% of plasma platinum was recovered in pUF. No platinum-DNA adducts in peripheral blood mononuclear cells (PBMCs) could be detected. Ex vivo incubation of DNA with pUF of patients revealed that up to 10% of the reactivity of platinum species was retained. Protein binding proceeded during sample storage. Sodium thiosulfate (STS) appeared to release platinum from the plasma proteins. Platinum levels were related to time, dose, STS co-administration, and glomerular filtration rates (GFR).

Conclusion: Our data suggest that plasma platinum levels are related to time, age, dose, GFR, and STS use. Platinum in plasma, probably, represent platinum eliminated from regenerating tissue. Platinum species in pUF were partly present in a reactive form. The effects of the reactivity on long-term consequences of Pt-containing chemotherapy, however, remains to be established.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
顺铂和奥沙利铂治疗后长期铂潴留。
背景:本研究的目的是评估接受顺铂和奥沙利铂治疗的患者的长期铂潴留。方法:纳入45例患者,在参加本研究前治疗8-75个月。测定血浆和血浆超滤液(pUF)中铂的含量。此外,还对铂在pUF中的反应性进行了评价。评估了铂保留与可能的决定因素之间的关系。结果:铂血药浓度范围为142 ~ 2.99 × 10(3) ng/L。在pUF中可回收高达24%的血浆铂。外周血单核细胞(PBMCs)未检出铂- dna加合物。用pUF对患者的DNA进行体外孵育,发现高达10%的铂类反应性被保留。在样品储存过程中进行蛋白质结合。硫代硫酸钠(STS)似乎从血浆蛋白中释放铂。铂水平与时间、剂量、STS联合给药和肾小球滤过率(GFR)有关。结论:我们的数据表明血浆铂水平与时间、年龄、剂量、GFR和STS使用有关。血浆中的铂,可能代表再生组织中消除的铂。铂在pUF中部分以反应态存在。然而,反应性对含pt化疗的长期后果的影响仍有待确定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Statin therapy in critical illness: an international survey of intensive care physicians' opinions, attitudes and practice. Correction: Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria Data for drugs available through low-cost prescription drug programs are available through pharmacy benefit manager and claims data. Population prevalence of high dose paracetamol in dispensed paracetamol/opioid prescription combinations: an observational study. Adherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian population.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1